Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

A Single-Center, Randomized Controlled Trial of Transcoronary Radiofrequency Ablation Versus Transcoronary Alcohol Ablation for Hypertrophic Obstructive Cardiomyopathy

16. November 2026 aktualisiert von: Ligang Ding

Patients with hypertrophic obstructive cardiomyopathy (HOCM) require septal reduction therapy to relieve left ventricular outflow tract obstruction (LVOTO). Septal myectomy is an open surgical procedure that resects hypertrophied septal myocardium to reduce outflow tract obstruction. However, it is associated with relatively substantial trauma. Some patients cannot tolerate surgery due to comorbidities or decline open-chest surgery.

Transcoronary alcohol ablation is a classic minimally invasive septal reduction therapy with a clinical history of nearly 30 years. Alcohol ablation induces myocardial injury via a chemical agent to reduce septal hypertrophy, widen the left ventricular outflow tract, lower the systolic pressure gradient, and improve clinical symptoms. It serves as a minimally invasive alternative to surgery. Nevertheless, the efficacy of this technique is highly dependent on the anatomical features of septal branches. Suboptimal outcomes may occur in some patients owing to variable septal branch anatomy. In addition, due to the high myocardial permeability of alcohol, atrioventricular block occurs in approximately 20% of patients after the procedure.

In recent years, transcoronary radiofrequency ablation has emerged as a novel minimally invasive septal reduction approach in clinical practice. For radiofrequency ablation, a microcatheter is advanced over a coronary guidewire into the septal branch. The proximal end of the guidewire is connected to a radiofrequency ablation generator, and myocardial ablation is delivered around the guidewire tip. Occlusion of the septal branch may further potentiate the ablative effect. This technique is less limited by anatomical variations of septal branches, features a shorter learning curve, and may have less impact on the conduction system. Compared with alcohol ablation, it enables more precise ablation with potentially superior safety. Both minimally invasive strategies achieve an obstruction relief rate exceeding 90%. To date, head-to-head data comparing the efficacy and safety profiles of these two minimally invasive therapies remain absent. Therefore, this randomized controlled trial is designed to compare the efficacy and safety of transcoronary alcohol ablation versus transcoronary radiofrequency ablation for hypertrophic obstructive cardiomyopathy.

You will be randomized in a 1:1 ratio to either the transcoronary alcohol ablation group or the transcoronary radiofrequency ablation group using a block randomization schedule. The probability of assignment to either group is 50%.

After randomization, cardiopulmonary exercise testing data, laboratory results and echocardiographic data will be collected at baseline, and the impact of cardiomyopathy on your quality of life will be assessed. Procedures in both groups will be performed by designated operators of the study team following standardized protocols. You will be blinded to the assigned treatment. In both groups, SonoVue will be injected into the coronary septal branch intraoperatively, and transthoracic echocardiography will be used to confirm that the ablation target is the critical site responsible for obstruction to ensure precise treatment. In the alcohol ablation group, 2-3 mL of absolute alcohol will be injected into the septal branch. In the radiofrequency ablation group, the guidewire will be connected to the radiofrequency generator; ablation energy will be set at 30-40 W, with 3 ablation applications of 30 seconds each at a single target site. Intraoperative electrocardiogram, heart rate, blood pressure and symptoms will be closely monitored, and the pressure gradient will be measured in real time using catheters and ultrasound. All patients will receive standardized medical therapy after the procedure. You will attend an outpatient follow-up visit at 3 months post-procedure, where repeat cardiopulmonary exercise testing, laboratory tests and echocardiography will be performed, and the post-procedure impact of cardiomyopathy on your quality of life will be re-evaluated. The primary endpoint of this study is the improvement in peak oxygen consumption on cardiopulmonary exercise testing at 3 months after treatment. No blood or tissue samples will be collected or stored for this study.

Studienübersicht

Studientyp

Interventionell

Einschreibung (Geschätzt)

80

Phase

  • Unzutreffend

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

    • Beijing Municipality
      • Beijing, Beijing Municipality, China, 100037
        • Rekrutierung
        • Fuwai Hospital, Chinese Academy of Medical Sciences
        • Kontakt:

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre und älter (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  • 1. Age > 18 years; 2. Diagnosis of hypertrophic obstructive cardiomyopathy (HOCM), with resting LVOTG > 50 mmHg measured by echocardiography or cardiac catheterization; 3. Persistent symptoms despite treatment with maximally tolerated doses of beta-blockers or calcium channel blockers (CCBs); 4. New York Heart Association (NYHA) functional class II or higher; 5. Echocardiographic confirmation that the obstruction originates from the interventricular septum at the left ventricular outflow tract; 6. Suitable septal branch visualized on coronary angiography, with contrast echocardiography confirming its perfusion territory corresponds to the target ablation site; 7. Interventricular septal thickness < 30 mm; 8. High surgical risk or explicit patient refusal of septal myectomy; 9. Ability to understand the study purpose, voluntary participation, and provision of written informed consent.

Exclusion Criteria:

  • Patients with severe mitral regurgitation secondary to organic mitral valve disease or other cardiac structural abnormalities requiring surgical intervention; Patients with significant stenosis of the left anterior descending coronary artery requiring percutaneous coronary intervention; Patients with bradyarrhythmia who have an indication for permanent pacemaker implantation; Patients with prior history of septal reduction therapy; Patients receiving myosin inhibitor therapy; Patients with severe hepatic or renal dysfunction; Patients with contraindications to coronary angiography and percutaneous interventional procedures; Patients with severe heart failure or cardiogenic shock who cannot maintain a supine position; Patients with a history of anaphylactic shock induced by contrast media; Patients considered ineligible for enrollment for other reasons at the investigator's discretion; Patients with pre-existing complete left bundle branch block at baseline.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Keine (Offenes Etikett)

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: transcoronary radiofrequency ablation

Both groups received SonoVue injection into the septal branch, and transthoracic echocardiography was used to confirm that the ablation site was the critical lesion responsible for obstruction. In the TCRFA group, a microcatheter was advanced over a coronary guidewire into the septal branch; the proximal end of the guidewire was connected to a radiofrequency ablation generator, and myocardial ablation was delivered around the guidewire tip. The ablation power was set at 30-40 W, with three applications of 30 seconds each at a single target site. Intraoperatively, electrocardiogram, heart rate, blood pressure and symptoms were closely monitored in both groups, and the left ventricular outflow tract gradient (LVOTG) was measured in real time via catheter and ultrasound. For patients in the TCRFA group whose post-treatment LVOTG failed to meet the criteria for obstruction relief, supplementary endocardial ablation would be performed intraoperatively to achieve the target reduction of LVO

Both groups received SonoVue injection into the septal branch, and transthoracic echocardiography was used to confirm that the ablation site was the critical lesion responsible for obstruction. In the TCRFA group, a microcatheter was advanced over a coronary guidewire into the septal branch; the proximal end of the guidewire was connected to a radiofrequency ablation generator, and myocardial ablation was delivered around the guidewire tip. The ablation power was set at 30-40 W, with three applications of 30 seconds each at a single target site. Intraoperatively, electrocardiogram, heart rate, blood pressure and symptoms were closely monitored in both groups, and the left ventricular outflow tract gradient (LVOTG) was measured in real time via catheter and ultrasound. For patients in the TCRFA group whose post-treatment LVOTG failed to meet the criteria for obstruction relief, supplementary endocardial ablation would be performed intraoperatively to achieve the target reduction of LVOT

Andere Namen:
  • TCRFA
Aktiver Komparator: transcoronary alcohol ablation

SonoVue is injected into the septal branch, and transthoracic echocardiography is used to confirm that the ablation site is the critical site causing obstruction. In the ASA group, 2-3 mL of absolute alcohol is injected into the septal branch. Intraoperatively, the patient's electrocardiogram, heart rate, blood pressure and symptoms are closely monitored, and LVOTG is measured in real time using catheters and ultrasound.

SonoVue is injected into the septal branch, and transthoracic echocardiography is used to confirm that the ablation site is the critical site causing obstruction. In the ASA group, 2-3 mL of absolute alcohol is injected into the septal branch. Intraoperatively, the patient's electrocardiogram, heart rate, blood pressure and symptoms are closely monitored, and LVOTG is measured in real time using catheters and ultrasound.

Andere Namen:
  • asa

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
absolute improvement in peak VO₂
Zeitfenster: baseline,3 months

Cardiopulmonary exercise testing is performed at baseline and at 3 months after the procedure to measure peak VO₂. The absolute improvement in peak VO₂ is defined as the post-procedure value minus the baseline value.

baseline,3 months
ncidence of new-onset complete left or right bundle branch block and/or permanent pacemaker implantation
Zeitfenster: baseline,3 months

The incidence of new-onset complete left bundle branch block, complete right bundle branch block, and/or permanent pacemaker implantation occurring from the time of the index procedure up to the 3-month post-procedure follow-up.

baseline,3 months

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Intraprocedural immediate reduction of LVOTG meeting criteria for obstruction relief
Zeitfenster: Intraoperatively

Proportion of participants with immediate intraprocedural LVOTG reduction that satisfies the predefined criteria for relief of left ventricular outflow tract obstruction.

Intraoperatively
Response rate of peak VO₂ at 3 months post-procedure
Zeitfenster: Baseline and 3 months after the procedure

Response rate is defined as the proportion of participants achieving a predefined improvement in peak VO₂ measured by cardiopulmonary exercise testing at 3 months post-procedure versus baseline.

Baseline and 3 months after the procedure
Reduction of LVOTG meeting obstruction relief criteria at 3 months post-procedure
Zeitfenster: Baseline and 3 months after the procedure

Proportion of participants whose LVOTG reduction meets the predefined obstruction relief criteria at 3-month follow-up.

Baseline and 3 months after the procedure
Absolute reduction of basal septal thickness
Zeitfenster: Baseline and 3 months after the procedure

Absolute difference in basal interventricular septal thickness between baseline and 3 months post-procedure, assessed by echocardiography.

Baseline and 3 months after the procedure
6-minute walk test distance
Zeitfenster: Baseline and 3 months after the procedure

Distance covered during the 6-minute walk test at baseline and at 3 months post-procedure.

Baseline and 3 months after the procedure
Canadian Cardiovascular Society (CCS) Angina Grade
Zeitfenster: Baseline and 3 months after the procedure

Change in Canadian Cardiovascular Society angina grade from baseline to 3 months post-procedure.

Baseline and 3 months after the procedure
Quality of life score
Zeitfenster: Baseline and 3 months after the procedure

Change in generic quality-of-life score from baseline to 3 months post-procedure.

Baseline and 3 months after the procedure
Kansas City Cardiomyopathy Questionnaire (KCCQ) score
Zeitfenster: Baseline and 3 months after the procedure

Change in Kansas City Cardiomyopathy Questionnaire (KCCQ) score from baseline to 3 months post-procedure.

Baseline and 3 months after the procedure
Improvement in New York Heart Association (NYHA) functional class
Zeitfenster: Baseline and 3 months after the procedure

Proportion of participants with improvement in New York Heart Association functional class at 3 months post-procedure compared with baseline.

Baseline and 3 months after the procedure

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Geschätzt)

16. November 2026

Primärer Abschluss (Geschätzt)

30. September 2027

Studienabschluss (Geschätzt)

31. Dezember 2027

Studienanmeldedaten

Zuerst eingereicht

16. November 2026

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

16. November 2026

Zuerst gepostet (Tatsächlich)

20. November 2026

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

20. November 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

16. November 2026

Zuletzt verifiziert

1. November 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

NEIN

Beschreibung des IPD-Plans

Individual participant data will not be shared to ensure patient confidentiality and comply with local institutional data protection policies.

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Abonnieren